ArticleFrontiers in pharmacology2025
The mechanism of Guanxin Qiwei dropping pills target
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Network Pharmacology-Serum Metabolomics Integration Identifies Key Targets, Biomarkers and Mechanism of Sendeng-4 in Rheumatoid Arthritis Therapy.International journal of general medicine · 2026Article
- RPN1 at the crossroads of glycosylation, tumor immunity, and disulfidptosis.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the therapeutic effects of Guanxin Qiwei dropping pills (GXQW) on atherosclerosis (AS) and to delineate the mechanisms underlying these effects. Methods: First, the chemical constituents of GXQW were identified using liquid chromatography-mass spectrometry (LC-MS). In addition, 15 batches of GXQW were used for fingerprint determination. Subsequently, an ApoE Results: A total of 118 chemical constituents were identified in GXQW through database comparison. Compared to the model group, GXQW treatment attenuated lipid deposition and plaque coverage in the aortic arch and mitigated collagen depletion. Fingerprint analysis showed the consistency and stability of the quality of GXQW. Additionally, GXQW reduced total cholesterol (TC) and triglyceride (TG) levels, decreased the concentrations of inflammatory cytokines interleukin-6 (IL-6) and interleukin-1beta (IL-1β), suppressed malondialdehyde (MDA) activity, and elevated superoxide dismutase (SOD) levels. In terms of gut microbiota modulation, high-dose GXQW treatment promoted the abundance of Conclusion: The findings suggest that GXQW exerts evident therapeutic effects on AS by regulating gut microbiota and serum metabolic biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.